<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01947790</url>
  </required_header>
  <id_info>
    <org_study_id>2013Wze051</org_study_id>
    <nct_id>NCT01947790</nct_id>
  </id_info>
  <brief_title>Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease</brief_title>
  <official_title>Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiang Guang-da</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular complications account for the highest mortality in type 2 diabetic patients,
      mainly due to ischeamia heart disease (IHD). Most of the attention in treating IHD in type 2
      diabetes is understandably directed toward treating coronary artery conditions. However there
      are other treatable culprits in these patients.

      Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with IHD, even
      in the absence of hypertension. It is a strong predictor of cardiovascular events and
      all-cause mortality. In one study, the presence of LVH was a stronger predictor of mortality
      than either multivessel coronary disease or impaired left ventricular function. Regression of
      LVH has been associated with an improved prognosis, independent of change in blood pressure
      (BP). Therefore, cardiovascular events and mortality in type 2 diabetes with IHD might will
      be reduced if we can find novel therapies to regress LVH.

      Pioglitazone can improve atherosclerosis. Therefore, we hypothesied that pioglitazone can
      regress the left ventricular mass (LVM) in type 2 diabetes with IHD.Therefore, in this study,
      we will treat patients with pioglitazone, and we will also metformin as control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of LVM</measure>
    <time_frame>The LVM will be measured at baseline, 6 momth and 9 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of endothelial function</measure>
    <time_frame>The endothelial function will be measured at baseline, 6 month and 9 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>LVM</condition>
  <condition>Type 2 Diabetic Patients With IHD</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>Pioglitazone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone 15 mg/day will be given in this group for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 0.85 twice daily will be given in this group for 9 months as control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone group</intervention_name>
    <arm_group_label>Pioglitazone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin group</intervention_name>
    <arm_group_label>Metformin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  aged 40ï½ž75 years old

          -  with IHD

        Exclusion Criteria:

          -  heart failure

          -  renal failure

          -  hypertension (&gt;130/80 mmHg)

          -  hemoglobin A1c 9%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Wuhan City</city>
        <state>Hubei</state>
        <zip>43000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiang Guangda</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2013</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>Xiang Guang-da</investigator_full_name>
    <investigator_title>Pioglitazone regress the left ventricular mass in normotensive type 2 diabetic patients with ischeamia heart disease</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>left ventricular mass</keyword>
  <keyword>pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

